When colorectal cancer reaches the liver
Colorectal cancer — cancer of the colon or rectum — is one of the most common cancers worldwide. In roughly 15 to 25 percent of patients, it has already spread to the liver by the time of diagnosis. This is called synchronous metastasis (meaning the spread happened around the same time as the original tumor was found).
Treating both the primary tumor and the liver metastases is essential for the best possible outcome. Traditionally, that meant two separate open surgeries — one to remove the colon tumor, and another, weeks or months later, to remove the liver lesions. That's two rounds of anesthesia, two hospital stays, two lengthy recoveries, and all the risks that come with each.
The case for doing it all at once
Surgeons began exploring simultaneous resection — removing both tumors in a single operation — to reduce the total burden on patients. Early studies using traditional open surgery showed it was possible, but the complexity was considerable and recovery was often difficult.
Then came minimally invasive approaches. Laparoscopic surgery (using small incisions and a camera) reduced some of the burden, but the technical demands of operating on two organs at once remained very high.
Robotic surgical systems offer some potential advantages here. Think of a robotic surgical system as a precision instrument that extends a surgeon's hands into a three-dimensional, magnified view of the body — with instruments that can bend and rotate in ways human wrists cannot. This extra dexterity may be especially useful when a surgeon needs to navigate from the abdomen to the liver in the same operation.
In robotic surgery, the surgeon sits at a console away from the operating table, controlling robotic arms that hold the instruments. The robotic system filters out hand tremor, enhances precision, and provides better visualization in tight spaces. For complex combined operations involving both the bowel and the liver, these capabilities may help surgeons complete the procedure without converting to open surgery — which adds time, blood loss, and recovery difficulty.
Researchers identified seven studies covering 165 patients who underwent robotic simultaneous resection for synchronous colorectal cancer and liver metastases. The average age was about 63 years. They tracked outcomes including how often the surgery had to convert to open, how long it took, how much blood was lost, serious complications, deaths within 30 days, leaks at the bowel connection point, and length of hospital stay.
The numbers behind the approach
The results were cautiously encouraging. The surgery was converted to an open procedure in only 3.9% of cases — a notably low rate given the complexity involved. Serious complications (Clavien-Dindo grade III or higher, meaning complications requiring additional procedures) occurred in 9.3% of patients. The 30-day mortality rate was 0.9% — less than 1 in 100 patients.
Crucially, R0 resection — meaning surgeons removed all visible cancer with clear margins — was achieved in 99% of cases. This is a key oncological benchmark. A positive margin (where cancer cells are found at the edge of what was removed) significantly increases the chance of recurrence.
The low conversion rate and near-universal clear margins suggest robotic assistance may offer real technical advantages for this complex procedure.
The average hospital stay was 6.7 days. Anastomotic leak — a serious complication where the reconnected bowel leaks — occurred in 4.3% of patients, which is within the range seen with conventional surgical approaches.
What surgeons are saying
The surgical community has been cautiously optimistic but appropriately careful. Simultaneous resection carries inherent risks — it is a longer, more complex operation than either procedure alone. But avoiding a second surgery has its own value: it reduces total anesthesia exposure, shortens the overall treatment timeline, and may allow chemotherapy to start sooner. The question is not whether robotic simultaneous resection is possible, but whether it is the right choice for a given patient — and who should be making that decision.
If you or a loved one has been told that colorectal cancer has spread to the liver and surgery is being considered, this research is worth discussing with your surgical team. Ask whether simultaneous resection — and robotic assistance specifically — is an option at your center. Not every hospital has robotic surgical capabilities or surgeons trained in this combined approach, so a referral to a specialized hepatobiliary (liver) or colorectal cancer center may be warranted.
This meta-analysis pooled only seven small observational studies totaling 165 patients — a limited evidence base for a complex question. There was no control group for direct comparison to open or laparoscopic simultaneous resection. Long-term survival data and cancer recurrence rates were not available. Patient selection criteria varied across studies, and the hospitals involved were likely centers of excellence with high surgical volumes, meaning results may not be replicable everywhere.
The authors call for larger, prospective studies comparing robotic simultaneous resection directly to laparoscopic and open approaches — with long-term follow-up on cancer recurrence and survival. As robotic surgical systems become more widely available and surgical training programs mature, the evidence base will grow. For now, this analysis provides early support that the approach is worth pursuing in selected patients at experienced centers — and that the question of one surgery versus two deserves a serious conversation between patients and their care teams.
